首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: Design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents
【24h】

Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: Design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents

机译:通过结构延伸增强碳酸酐酶IX活性部位内的尾疏水相互作用:设计和合成新型N-取代的ISATINS-SLC-0111杂交种作为碳酸酐酶抑制剂和抗肿瘤剂

获取原文
获取原文并翻译 | 示例
           

摘要

Herein we report the design and synthesis of novel N-substituted isatins-SLC-0111 hybrids (6a-f and 9a-1). A structural extension approach was adopted via N-alkylation and N-benzylation of isatin moiety to enhance the tail hydrophobic interactions within the carbonic anhydrase (CA) IX active site. Thereafter, a hybrid pharmacophore approach was utilized via merging the pharmacophoric elements of isatin and SLC-0111 in a single chemical framework. As planned, a substantial improvement of inhibitory profile of the target hybrids (K(I)s: 4.7-86.1 nM) towards hCA IX in comparison to N-unsubstituted leads IVa-c (K(I)s: 192-239 nM), was achieved. Molecular docking of the designed hybrids in CA IX active site unveiled, as planned, the ability of N-alkylated and N-benzylated isatin moieties to accommodate in a wide hydrophobic pocket formed by T73, P75, P76, L91, L123 and A128, establishing strong van der Waals interactions. Hybrid 6c displayed good anti-proliferative activity under hypoxic conditions towards breast cancer MDA-MB-231 and MCF-7 cell lines (IC50 = 7.43 +/- 0.28 and 12.90 +/- 0.34 mu M, respectively). Also, 6c disrupted the MDA-MB-231 cell cycle via alteration of the Sub-G(1) phase and arrest of G(2)-M stage. Additionally, 6c displayed significant increase in the percent of annexinV-FITC positive apoptotic cells from 1.03 to 18.54%. Furthermore, 6c displayed potent VEGFR-2 inhibitory activity (IC50 = 260.64 nM). Collectively, these data suggest 6c as a promising lead molecule for the development of effective anticancer agents. (C) 2018 Elsevier Masson SAS. All rights reserved.
机译:在此,我们报告了新型N-取代的ISATINS-SLC-0111杂交种(6A-F和9A-1)的设计和合成。通过N-烷基化和Isatin部分的N-苄化化采用结构延伸方法,以增强碳酸酐酶(CA)IX活性位点内的尾疏水相互作用。此后,通过在单个化学框架中合并Isatin和SLC-0111的药物元素来利用杂交药物方法。如计划,与N-Unsubstiteded ineva IVA-C(K(i)S:192-239nm)相比,靶向杂种(K(i)S:4.7-86.1nm)的抑制性抑制概况, 已实现。如计划,如计划,如计划,在Ca IX活性部位中的设计杂种的分子对接,N-烷基化和N-苄化的isatin部分在由T73,P75,P76,L91,L123和A128形成的宽疏水袋中,建立强大的范德沃尔斯互动。杂交6C在抗乳腺癌MDA-MB-231和MCF-7细胞系下显示良好的抗增殖活性,分别为乳腺癌MDA-MB-231和MCF-7细胞系(IC50 = 7.43 +/- 0.28和12.90 +/- 0.34 mu m)。此外,6C通过改变亚-g(1)相和捕获来破坏MDA-MB-231细胞周期和G(2)-M阶段。此外,6C显示出从1.03至18.54%的annexinv-Fitc阳性凋亡细胞百分比显着增加。此外,6C显示有效VEGFR-2抑制活性(IC50 = 260.64nm)。总的来说,这些数据表明6C作为有前途的铅分子用于开发有效的抗癌剂。 (c)2018年Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号